In patients with multiple system atrophy (MSA), sleep disorders, such as excessive daytime sleepiness, rapid eye movement (REM) sleep behavior disorder (RBD), and sleep-disordered breathing (SDB), are a common complaint [1]. SDB can manifest as stridor, obstructive sleep apnea (OSA), and central sleep apnea in these patients [1]. Central sleep apnea is more commonly reported in the later stages of MSA [1], and stridor is typically found together with OSA [2]. For patients with MSA, SDB can be life-threatening, and continuous positive airway pressure (CPAP) is recommended as the first-line therapy [2]. RBD develops in 90% to 100% of the patients, indicating a severe and extensive pathologic deficit in the central nervous system, which regulates REM sleep [2]. In patents with MSA, RBD usually occurs just prior to or at the onset of MSA and then disappears over the course of disease progression [2]. To our best knowledge, this is the first report of a MSA patient with SDB who developed RBD during CPAP titration.
Case Report
A 74-year-old woman presented to our hospital for evaluation of nocturnal respiratory disturbance and abnormal breathing sounds during sleep, which developed seven months prior to her initial visit. Four years earlier, she had noticed generalized bradykinesia with orthostatic hypotension and urge incontinence, and had been diagnosed with MSA with predominant parkinsonism. Her symptoms had gradually deteriorated, and she was bedridden at the time of presentation. Her husband reported that she had repeated nocturnal episodes of complex motor behaviors and sleep talking for 5 years, which had become less frequent and less severe over several months, and had disappeared four months prior to presentation. She had been administered 1,000 mg levodopa, 0.75 mg pramipexole, 150 mg itopride, 0.5 mg clonazepam, and 5 mg midodrine daily.
Overnight polysomnography (PSG) revealed frequent, severe, harsh high-pitched sounds in the inspiration phase (stridor) with many episodes of obstructive hypopnea (Fig. 1). The number of stridor events was 834.0/h of sleep time, and the apnea/hypopnea index (AHI) was 47.3/h. The lowest oxyhemoglobin saturation (SpO2) was 68%, and low SpO2 was continuously measured (average SpO2, 72.4%). Sleep architecture showed an increase in stages N1 and N2 sleep, decreased stage N3 sleep, and absent REM sleep.
Six weeks after the initial PSG, CPAP titration with PSG was performed. CPAP was administered using 4 to 13 cm H2O. During the titration with 11 cm H2O pressure, the patient had three episodes of talking and complex motor behaviors that were not observed in the initial PSG, with increased muscle tone during REM sleep, which was compatible with RBD (Fig.2). REM sleep (3.7% of total sleep stage) occurred after 244 minutes of latency, and was only present during the titration with 11 cm H2O pressure. A fixed CPAP pressure of 11 cm H2O was considered adequate for treatment of the SDB. With a pressure of 11 cm H2O, the AHI decreased to 4.7/h, lowest SpO2 was 83%, average SpO2 was 91.8%, and stridor was nearly eliminated.
Discussion
Marked sleep fragmentation in patients with MSA has been reported by several polysomnographic studies and is related to motor symptoms such as urinary incontinence, rigidity, and bradykinesia with subsequent inability to turn over in the bed [2].
Recently, two cases of RBD during CPAP titration were reported in Korean patients with OSA who developed RBD symptoms with increased REM sleep [3]. OSA can also lead to sleep fragmentation; hence, patients with the disease show an increase in light non-REM sleep, and a decrease in REM sleep and slow-wave sleep on PSG [4]. When CPAP is administered at the appropriate pressure level for OSA, respiratory obstructive events are eliminated; hence, the amounts of REM and slow-wave sleep increase [5,6].
Extensive research has shown that SDB is a frequent and major problem in patients with MSA [1]. One of the most typical types of SDB in MSA is stridor caused by upper airway obstruction that frequently accompanies OSA [2]. Such SDB can cause sleep fragmentation in patients with MSA, and CPAP is recommended as a first-line treatment for increased long-term survival [7]. In the present case, during a therapeutic trial of CPAP, when an adequate pressure level for the treatment of SDB was reached, REM sleep occurred, and consequently, RBD developed.
Although RBD is a common manifestation in patients with MSA, it does not present in the later stages of disease, and it can disappear with worsening disease condition [2,8]. These phenomena can be explained by progressive degeneration of the brain stem nuclei, which control REM sleep [2,9]. Furthermore, in cases like the present, sleep fragmentation might mask RBD in MSA patients with SDB. In addition, clonaze- pam, the first-line medication in the management of MSA patients with RBD, is known to worsen sleep apnea [10]; this drug might exacerbate SDB, and consequently might influence sleep fragmentation in patients with MSA.
In the present report, we illustrated the case of a MSA patient with SDB who developed RBD during CPAP titration. To our knowledge, this is the first case of its kind, and hence merits reporting. Both RBD and SDB are common manifestations of MSA [1]. Because RBD symptoms might affect CPAP adherence, physicians should carefully guide CPAP treatment in patients with MSA. Although MSA patients with SDB might have a history of RBD that has disappeared, clinicians should consider the presence of RBD symptoms during CPAP application with adequate pressure. Moreover, clonazepam treatment can exacerbate OSA and is associated with less optimal treatment outcomes in patients with RBD [11]; hence, the choice of other classes of drugs without respiratory effects, such as melatonin, and more optimized CPAP treatment should be considered in MSA patients with SDB.